论文部分内容阅读
【目的】探讨仙灵骨葆胶囊联合雌激素替代疗法治疗围绝经期综合征患者的临床疗效。【方法】选取2016年8月至2017年8月在本院诊治的围绝经期综合征患者82例，采用随机数表法分为观察组与对照组。对照组应用雌激素替代疗法，观察组在对照组基础上加用仙灵骨葆胶囊治疗，比较两组患者疗效、临床症状改善情况、不良反应发生率和治疗前后骨密度、血清卵泡刺激素（FSH）和黄体生成素（LH）、雌二醇（E2）水平。【结果】观察组患者治疗有效率为97.56%(40/41)，显著高于对照组的80.49%（33/41）,其差异有统计学意义（χ2=4.493,P=0.034）；观察组患者Kupperman评分、血清FSH、LH水平显著低于对照组，脊椎骨密度、股骨颈骨密度、E2水平均显著高，其差异均有统计学意义（P<0.05）；观察组患者不良反应发生率为4.88%(2/41)，显著高于对照组的24.39%（10/41），其差异有统计学意义（χ2=4.783,P=0.029）。【结论】仙灵骨葆胶囊联合雌激素替代疗法治疗围绝经期综合征患者的疗效确切，临床症状减轻，骨密度明显提高，并可改善血清FSH、LH水平、促进卵巢功能有效恢复，且无明显不良反应，值得临床推广应用。nn|%【Objective】To investigate the influences of Xianling Gubao capsule combined with estrogen replacement therapy on the clinical symptoms, bone density and serum follicle stimulating hormone (FSH) and luteinizing hormone (LH) in perimenopausal syndrome patients. 【Methods】Eightytwo cases of patients with perimenopausal syndrome in our hospital from August 2016 to August 2017 were selected. Patients were divided into the observation group and the control group by random alphabet. The control group was treated with estrogen replacement therapy, while the observation group was treated with Xianling Gubao capsule in addition to estrogen replacement. The therapeutic effect, adverse reactions and clinical symptoms improvement of the two groups were compared The bone mineral density and serum FSH, LH and estradiol (E2) levels were measured and compared before and after treatment. 【Results】The effective rate of the observation group was 97.56% (40/41), which was significantly higher than 80.49% (33/41) of the control group (P<0.05). Kupperman score of the observation group was significantly lower than that of the control group, and the difference was statistically significant (P<0.05). Compared to the control group, the mean vertebral bone density and mean femoral neck bone density were higher in the observation group (P<0.05). In comparison with the control group, the serum FSH and LH levels in the observation group were significantly decreased, while serum E2 level increased significantly (P<0.05); the incidence of adverse reactions in the observation group(4.88%) was significantly lower than that in the control group(24.39%), and the difference was statistically significant (P<0.05). 【Conclusion】The application of Xianling Gubao capsule combined with estrogen replacement therapy has achieved satisfactory clinical effect in the treatment of perimenopausal syndrome, which clinical symptoms are relieved, bone density is increased significantly, the levels of serum FSH and LH are improved. It can promote the effective recovery of ovarian function, at the same time, there was no obvious adverse reaction.